CDKN2A and melanoma: Promoter hypermethylation of CDKN2A leading to transcription silencing and loss of protein expression increases during melanoma progression and has been identified in approximately 19–60% of vertical-growth-phase melanomas, 40% of radial-growth-phase melanomas, and 25–33% of melanoma metastases [25,26,27,28].